{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:14:41Z","timestamp":1791918881795,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,5,29]],"date-time":"2008-05-29T00:00:00Z","timestamp":1212019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00280-008-0771-1","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T05:56:19Z","timestamp":1211954179000},"page":"1091-1101","source":"Crossref","is-referenced-by-count":20,"title":["Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion"],"prefix":"10.1007","volume":"62","author":[{"given":"Alan P.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia L.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay A.","family":"Criswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Holliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Evering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart A.","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,29]]},"reference":[{"issue":"7","key":"771_CR1","first-page":"2482","volume":"91","author":"F Arguello","year":"1998","unstructured":"Arguello F, Alexander M, Sterry JA, Gabriela T, Smith EM, Kalavar NT, Greene JF, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91(7):2482\u20132490","journal-title":"Blood"},{"issue":"15","key":"771_CR2","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","volume":"66","author":"LB Baughn","year":"2006","unstructured":"Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MAS, Chen-Kiang S (2006) A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6. Cancer Res 66(15):7661\u20137667","journal-title":"Cancer Res"},{"key":"771_CR3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0301-472X(01)00619-1","volume":"29","author":"JR Fink","year":"2001","unstructured":"Fink JR, LeBien TW (2001) Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors. Exp Hematol 29:490\u2013498","journal-title":"Exp Hematol"},{"issue":"6","key":"771_CR4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1517\/13543784.12.6.955","volume":"12","author":"PM Fischer","year":"2003","unstructured":"Fischer PM, Gianella-Borradori A (2003) CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 12(6):955\u2013970","journal-title":"Expert Opin Investig Drugs"},{"issue":"20","key":"771_CR5","doi-asserted-by":"crossref","first-page":"16617","DOI":"10.1074\/jbc.M008867200","volume":"276","author":"DW Fry","year":"2001","unstructured":"Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD (2001) Cell cycle and biochemical effects of PD 0183812, a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem 276(20):16617\u201316623","journal-title":"J Biol Chem"},{"issue":"11","key":"771_CR6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3(11):1427\u20131437","journal-title":"Mol Cancer Ther"},{"key":"771_CR7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.1365-2141.2000.02253.x","volume":"110","author":"Y Furukawa","year":"2000","unstructured":"Furukawa Y, Kikuchi J, Nakamura M, Iwase S, Yamada H, Matsuda M (2000) Lineage-specific regulation of cell cycle control gene expression during haematopoetic cell differentiation. Br J Haematol 110:663\u2013673","journal-title":"Br J Haematol"},{"key":"771_CR8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0959-437X(99)80015-X","volume":"9","author":"MD Garrett","year":"1999","unstructured":"Garrett MD, Fattaey A (1999) CDK inhibition and cancer therapy. Curr Opin Genet Dev 9:104\u2013111","journal-title":"Curr Opin Genet Dev"},{"key":"771_CR9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jat.1177","volume":"27","author":"BA Jessen","year":"2007","unstructured":"Jessen BA, Lee L, Koudriakova T, Haines M, Lundgren K, Price S, Nonomiya J, Lewis C, Stevens GJ (2007) Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol 27:133\u2013142","journal-title":"J Appl Toxicol"},{"issue":"3","key":"771_CR10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<546::AID-CNCR5>3.0.CO;2-0","volume":"85","author":"JH Kim","year":"1999","unstructured":"Kim JH, Kang MJ, Park CU, Kwak HJ, Hwang Y, Koh GY (1999) Amplified CDK2 and cdc2 activities in primary colorectal carcinoma. Cancer 85(3):546\u2013553","journal-title":"Cancer"},{"key":"771_CR11","first-page":"43","volume":"3","author":"TC Ko","year":"1997","unstructured":"Ko TC, Bresnahan WA, Thompson EA (1997) Intestinal cell cycle regulation. Prog Cell Cycle Res 3:43\u201352","journal-title":"Prog Cell Cycle Res"},{"key":"771_CR12","doi-asserted-by":"crossref","unstructured":"O\u2019Dwyer PJ, LoRussso P, DeMichele A, Gupta V, Barbi A, Dials H, Chen I, Courtney R, Wilner K, Schwartz GK (2007). Phase I dose escalation trial of a daily oral CDK 4\/6 inhibitor PD-0332991. J Clin Oncol. 2007 ASCO annual meeting proceed part 1. vol 25. no 18S (abstract 3550)","DOI":"10.1200\/jco.2007.25.18_suppl.3550"},{"key":"771_CR13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/01926230500455862","volume":"33","author":"F Ramiro-Ibanez","year":"2005","unstructured":"Ramiro-Ibanez F, Trajkovic D, Jessen B (2005) Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor. Toxicol Pathol 33:784\u2013791","journal-title":"Toxicol Pathol"},{"issue":"24","key":"771_CR14","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1158\/1078-0432.CCR-07-2141","volume":"13","author":"O Rixe","year":"2007","unstructured":"Rixe O, Fojo T (2007) Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 13(24):7280\u20137287","journal-title":"Clin Cancer Res"},{"key":"771_CR15","doi-asserted-by":"crossref","first-page":"4270s","DOI":"10.1158\/1078-0432.CCR-040020","volume":"10","author":"GI Shapiro","year":"2004","unstructured":"Shapiro GI (2004) Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res (suppl) 10:4270s\u20134275s","journal-title":"Clin Cancer Res (suppl)"},{"key":"771_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0968-0004(00)89005-2","volume":"20","author":"CJ Sherr","year":"1995","unstructured":"Sherr CJ (1995) D-type cyclins. Trends Biol Sci 20:187\u2013190","journal-title":"Trends Biol Sci"},{"key":"771_CR17","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","volume":"274","author":"CJ Sherr","year":"1996","unstructured":"Sherr CJ (1996) Cancer cell cycles. Science 274:1672\u20131677","journal-title":"Science"},{"issue":"2","key":"771_CR18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.2000.18.2.371","volume":"18","author":"WM Stadler","year":"2000","unstructured":"Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE (2000) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II consortium study. J Clin Oncol 18(2):371\u2013375","journal-title":"J Clin Oncol"},{"issue":"19","key":"771_CR19","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2002.01.043","volume":"20","author":"AR Tan","year":"2002","unstructured":"Tan AR, Headlee D, Messman R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM (2002) Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20(19):4074\u20134082","journal-title":"J Clin Oncol"},{"key":"771_CR20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1535-6108(03)00053-9","volume":"3","author":"O Tetsu","year":"2003","unstructured":"Tetsu O, McCormick F (2003) Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3:233\u2013245","journal-title":"Cancer Cell"},{"key":"771_CR21","unstructured":"Zhang CC, Kephart S, McAlpine I, Nonomiya J, Higgins J, Arango ME, Yan Z, Knighton D, Ferre RA, Tikhe J, Verkhivker G, Xu M, Romines W, Palmer C, Park J, Reich S, Chong W, Li L, Los G, Lewis C (2005) AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity. Proc Am Assoc Cancer Res 46 (abstract 4415)"},{"key":"771_CR22","unstructured":"Zhang CC, Troche G, Yan Z, Arango ME, Higgins J, Romero D, Kephart S, McAlpine I, Koudriakova T, Skaptason J, Nonomiya J, Knighton D, Ferre RA, Tikhe J, Verkhivker G, Xu M, Romines W, Palmer C, Park J, Reich S, Los G, Lewis C (2005) AG-024322 is a multi-targeted CDK inhibitor with potent antitumor activity in vivo. Proc Am Assoc Cancer Res 46 (abstract 4413)"},{"key":"771_CR23","first-page":"169","volume":"57","author":"T Zhang","year":"1997","unstructured":"Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD (1997) Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res 57:169\u2013175","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0771-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0771-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:34:00Z","timestamp":1684420440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0771-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,29]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0771-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,29]]}}}